Investor Presentation

Novo NordiskⓇ 100 Investor presentation First six months of 2022 Evoke and evoke+ trials are ongoing with expected completion in 2025 evoke and evoke+ trials have been initiated with 1,840 patients in each trial with a total of 3,680 patients 7 mg 3 mg R 7 mg 3 mg 151 1:1 Week 0 4 00 14 mg oral semaglutide QD 14 mg oral semaglutide QD 14 mg placebo QD 14 mg placebo QD + 104 Treatment period ↑ Confirmatory endpoints 156 161 Follow-up • Age between 55-85 years • evoke+ has at least 20% with small vessel pathology Objective To confirm superiority of oral semaglutide vs placebo on the change in cognition and function in people with early Alzheimer's disease Primary endpoint Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score from baseline to end of 104 weeks of treatment Inclusion criteria • Early Alzheimer's disease (mild cognitive impairment or mild dementia) Mini-Mental State Examination (MMSE) ≥ 22/30 AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; QD: once-daily. Note: CDR-SB ratings are utilising in six domains are summed to provide a clinical measure = Sum of Boxes. These are: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care. CDR-SB Scores range from 0 to 18 with higher scores representing greater impairment

View entire presentation